- Home
- NEGG vs MOLN Comparison
NEGG vs MOLN Comparison
Compare NEGG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- MOLN
- Stock Information
- Founded
- NEGG 2001
- MOLN 2004
- Country
- NEGG United States
- MOLN Switzerland
- Employees
- NEGG N/A
- MOLN N/A
- Industry
- NEGG Other Specialty Stores
- MOLN
- Sector
- NEGG Consumer Discretionary
- MOLN
- Exchange
- NEGG Nasdaq
- MOLN Nasdaq
- Market Cap
- NEGG 122.3M
- MOLN 142.6M
- IPO Year
- NEGG 2010
- MOLN 2021
- Fundamental
- Price
- NEGG $47.12
- MOLN $3.64
- Analyst Decision
- NEGG
- MOLN Hold
- Analyst Count
- NEGG 0
- MOLN 1
- Target Price
- NEGG N/A
- MOLN $4.00
- AVG Volume (30 Days)
- NEGG 2.2M
- MOLN 5.1K
- Earning Date
- NEGG 08-29-2025
- MOLN 11-05-2025
- Dividend Yield
- NEGG N/A
- MOLN N/A
- EPS Growth
- NEGG N/A
- MOLN N/A
- EPS
- NEGG N/A
- MOLN N/A
- Revenue
- NEGG $1,313,127,000.00
- MOLN $856,302.00
- Revenue This Year
- NEGG N/A
- MOLN N/A
- Revenue Next Year
- NEGG N/A
- MOLN $1,000.00
- P/E Ratio
- NEGG N/A
- MOLN N/A
- Revenue Growth
- NEGG N/A
- MOLN N/A
- 52 Week Low
- NEGG $3.32
- MOLN $3.36
- 52 Week High
- NEGG $137.84
- MOLN $7.60
- Technical
- Relative Strength Index (RSI)
- NEGG 47.16
- MOLN 48.03
- Support Level
- NEGG $33.52
- MOLN $3.69
- Resistance Level
- NEGG $48.15
- MOLN $3.79
- Average True Range (ATR)
- NEGG 7.85
- MOLN 0.13
- MACD
- NEGG -1.05
- MOLN 0.00
- Stochastic Oscillator
- NEGG 56.19
- MOLN 18.18
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.